Op 15 januari 2013 heeft onze CEO Henk-Peter Oonk in Vancouver het contract getekend voor de distributie van Verisante Aura in Scandinavië.
bo pharma was al distributeur van dit revolutionaire huidkankerdetectie device in de Benelux. Hier komen nu de landen Noorwegen, Zweden, Finland, Denemarken en IJsland bij.
Hierbij het persbericht dat Verisante heeft verstuurd:
Verisante Technology, Inc. announces expansion of exclusive distribution agreement with bo pharma into Nordic Countries
Innovative skin cancer device will be available in Sweden, Norway, Denmark, Finland en IJsland
VANCOUVER, BRITISH COLUMBIA – Verisante Technology, Inc., a leader in cancer detection technology, announced today that the Company has amended its exclusive agreement with bo pharma to distribute Verisante Aura™ in the Nordic countries of Sweden, Norway, Denmark, Finland and Iceland; in addition to Belgium, the Netherlands and Luxemburg (“Benelux”).
“bo pharma is committed to expanding its distribution facilities into this region,” said Thomas Braun, President & CEO of Verisante. “With this foundation and bo pharma’s experience and expertise in distributing the world’s top brands in dermatological and skin care devices; this provides us with an excellent opportunity to expand our partnership into this important region. bo pharma has the resources to both distribute Aura™, and provide support, technical training and servicing in the Nordic countries.”
Last year, Aura™ received the Conformite Europeenne (CE) Mark approval, which is recognized by all the 27 Member States of the EU, including Sweden, Denmark and Finland, which, along with Norway and Iceland (who, while not members of the EU, are European Economic Area signatories and accept the CE Mark), have a total population of over 25 million people, and approximately 1,000 dermatologists serving the region.
Game changing device
“Aura™ is a game changing device in the field of skin cancer diagnosis,” said Dr. Henk-Peter Oonk, CEO of bo pharma. “We anticipate significant demand of this new technology in Benelux and welcome the opportunity to widen this adoption into the Nordic countries, where bo pharma has rapid expansion plans.”
Verisante Aura™ is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma when a medical professional chooses to obtain additional information to rule out one of the above conditions before making a final decision to biopsy. Aura™ is a non-invasive optical system that uses Raman spectroscopy to biochemically analyze the skin, providing immediate and accurate results. The device will help to automate the current process of diagnosis, allowing rapid scanning of the 20 to 40 skin lesions on at-risk individuals, improving patient outcomes and comfort.